Search
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnBinding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly. … Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Elvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalAlthough available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug. … Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.
Pretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigationalPersistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. … It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019.
Vanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigational], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations. … Vanzacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) corrector.
Goserelin
go.drugbank.com/drugs/DB00014ApprovedInvestigationalGoserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. … In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state.
Lapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor.
GC-376 free acid
go.drugbank.com/drugs/DB15796ExperimentalA prodrug of [GC-373], GC-376 has recently been used to test inhibition of SARS-Cov-2 M<sup>pro</sup> _in vitro_, and results show potent inhibition of this target[A219036]. … The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056].
Florbetapir F-18
go.drugbank.com/drugs/DB09149ApprovedInvestigationalFlorbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide … that plays a key role in Alzheimer's Disease pathogenesis.
Iproniazid
go.drugbank.com/drugs/DB04818ApprovedWithdrawnWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesIloprost
go.drugbank.com/drugs/DB01088ApprovedInvestigational[A263326] Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47.[L50146] It is a potent vasodilator with reported anti-thrombotic properties. … Iloprost is an analog of prostacyclin (PGI2; epoprostenol), an endogenous prostanoid mainly produced in the vascular endothelium. It is more stable than prostacyclin, which is short-lived.